Mr. Roger DuMoulin-White reports

THERALASE RECEIVES RECEIPT FOR C$100 MILLION BASE SHELF PROSPECTUS

Theralase Technologies Inc. has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026, with the securities regulatory authorities in all provinces and territories of Canada.

The prospectus will allow Theralase to offer up to $100-million of common shares, warrants, subscription receipts, debt securities or any combination thereof over a 25-month period.

Roger DuMoulin-White, BSc, PEng, ProDir, president and chief executive officer of Theralase, stated: "The approval of the prospectus represents an important milestone for the company, providing up to $100-million of capital, if and when required, to fund the commercial development of various cancer, virus and bacteria platforms. Access to capital markets, as opportunities arise, supports our corporate strategy of simultaneously advancing numerous, value-driven strategic initiatives, including: our pivotal non-muscle invasive bladder cancer clinical program, our pipeline of various oncological conditions and the continued development of our pharmaceutical platform. The company believes that maintaining access to flexible financing will support its ongoing efforts to create long-term shareholder value through successful achievement of key clinical, regulatory and commercial milestones."

Any future offering under the prospectus will be made by way of a prospectus supplement containing specific terms of the offering, and will be filed with the applicable securities regulatory authorities. The company has no present intention to offer the securities pursuant to the prospectus.

For a copy of the prospectus, please refer to the company's SEDAR+ profile.

About Theralase Technologies Inc.

Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.

We seek Safe Harbor.